Bill Gates Says Alzheimer’s Breakthrough Is Here — But the System Is Failing Patients

Key takeaways

• Alzheimer’s breakthroughs exist, but the system is not ready to deliver them fast enough to patients.
• First two blood tests available last year
• Two more blood tests approved in August
• Two antibody therapies approved by FDA

What happened

Bill Gates highlighted that Alzheimer’s disease now has blood‑based diagnostics and FDA‑approved antibody therapies, but the healthcare system is not delivering them quickly enough to patients. The first two blood tests were available last year and two more received FDA approval in August. Two antibody drugs that clear amyloid have been approved, and a home‑injectable version was cleared in July. Gates warned that awareness, access, cost, and logistical hurdles are slowing uptake.

Why it matters

These advances could shift Alzheimer’s from a helpless condition to one where early detection and treatment are possible. If the system fails to adopt the new tests and therapies, patients may miss the window where intervention is most effective, undermining the potential benefits of the science. Gates’ comments…

Short-term and longer-term

Short-term. In the next few weeks, watch for any updates from Medicare or state insurers on coverage for the new blood tests, as changes could trigger a price spike for diagnostic labs.

Longer-term. Over the coming months, the broader Alzheimer’s market could see a shift toward companies that can navigate payer negotiations and streamline patient access.